MARKET

ARQT

ARQT

Arcutis Biotherapeutics, Inc.
NASDAQ
24.17
+0.25
+1.05%
After Hours: 24.17 0 0.00% 16:15 10/07 EDT
OPEN
23.74
PREV CLOSE
23.92
HIGH
24.38
LOW
23.51
VOLUME
1.70M
TURNOVER
--
52 WEEK HIGH
31.77
52 WEEK LOW
19.30
MARKET CAP
3.04B
P/E (TTM)
112.68
1D
5D
1M
3M
1Y
5Y
1D
Arcutis Biotherapeutics: An Emerging GARP Stock
Seeking Alpha · 1d ago
Arcutis: Every Beat Gets Absorbed By A Shrinking Multiple (Rating Downgrade)
Seeking Alpha · 1d ago
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Barchart · 1d ago
Weekly Report: what happened at ARQT last week (0928-1002)?
Weekly Report · 2d ago
Arcutis Biotherapeutics partners with Simone Biles for new awareness campaign
TipRanks · 09/29 13:20
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
Barchart · 09/29 08:15
Weekly Report: what happened at ARQT last week (0921-0925)?
Weekly Report · 09/28 10:04
3 Healthcare ETFs for FDA-Approved Profits
Barchart · 09/23 10:15
More
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.

Webull offers Arcutis Biotherapeutics Inc stock information, including NASDAQ: ARQT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARQT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARQT stock methods without spending real money on the virtual paper trading platform.